Which Factors Will Push The Liquid Biopsy For Cancer Diagnostics Market To Achieve $19.24 Billion By 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Projected Valuation Of The Liquid Biopsy For Cancer Diagnostics Market In The Coming Years?
The market size for liquid biopsy in cancer diagnostics has seen a significant expansion lately. From $9.23 billion in 2024, it is projected to escalate to $10.76 billion in 2025, with a compound annual growth rate (CAGR) of 16.6%. This growth during the historic period is largely driven by progress made in genomic research, increasing awareness about the advantages of liquid biopsy, a higher incidence of cancer, surging demand for non-invasive cancer tests, and the expanded implementation of precision medicine initiatives.
The market size for liquid biopsy in cancer diagnostics is anticipated to experience a swift expansion in the upcoming years, reaching $19.24 billion in 2029 with a compound annual growth rate (CAGR) of 15.6%. The projected growth in the forecast period can be ascribed to the introduction of liquid biopsy into routine cancer diagnostics, the uptake of liquid biopsy for the early detection of cancer, the expansion of cancer screening programs, an escalating focus on personalized medicine within oncology, and increased investment in research on liquid biopsy. Key trends predicted for the forecast period include the emergence of multi-omics liquid biopsy methodologies, the incorporation of artificial intelligence into liquid biopsy analysis, the broadening of liquid biopsy applications beyond oncology, the development of blood-centric biomarkers for cancer, and the tailoring of liquid biopsy tests for particular types of cancer.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp
Which Growth Drivers Are Shaping The Liquid Biopsy For Cancer Diagnostics Market Outlook?
The liquid biopsy for cancer diagnostics market is projected to grow, driven by the increasing prevalence of cancer. Cancer encompasses a range of diseases that occur when cells multiply uncontrollably beyond their usual limits and subsequently invade surrounding areas or spread to other organs. The necessity for diagnostic procedures including early detection of cancer or tumor recurrence, patient-specific risk assessment, and therapeutic monitoring are magnified by cancer. Liquid biopsy offers a comprehensive view of the disease’s full range as metastatic or primary tumor sites release tumor cells or tumor cell by-products, delivering detailed, real-time data on tumor cell evolution, targets for therapy, and therapy resistance mechanisms. As per the National Cancer Institute, a US government agency, the number of cancer survivors in the US stood at approximately 18.1 million in May 2024. This number is anticipated to increase to 22.5 million by 2032 and by 2040, an estimated 29.9 million new cancer cases are forecasted annually, with cancer-related deaths expected to rise to 15.3 million. Hence, the escalating occurrence of cancer is fueling the expansion of the liquid biopsy for cancer diagnostics market.
What Is The Segment Breakdown Of The Liquid Biopsy For Cancer Diagnostics Market?
The liquid biopsy for cancer diagnosticsmarket covered in this report is segmented –
1) By Type: Product; Services
2) By Sample: Blood; Urine; Saliva
3) By Cancer: Lung Cancer; Breast Cancer; Colon Cancer; Other Cancers
4) By End-User: Hospitals; Diagnostic Centers; Other End-Users
Subsegments:
1) By Product: Circulating Tumor Cells (CTCs) Detection Kits; Circulating Tumor DNA (ctDNA) Detection Kits; Exosome Isolation Kits; Sample Collection Devices
2) By Services: Testing Services; Analytical Services; Bioinformatics Services
What Are The Dominant Trends Currently Seen In The Liquid Biopsy For Cancer Diagnostics Market?
One noteworthy trend in the liquid biopsy for cancer diagnostics market is the rising popularity of product innovations. To consolidate their market presence, prominent firms in this sector are focusing on introducing pioneering products. As an example, BostonGene, a biomedical software company from the United States, unveiled new liquid biopsy solutions aiming to detect significant gene alterations in June 2023. This expanded test collection will expedite the development of new assays, analysis tools, and workflows to offer precision medicine to patients. These tests will integrate multiple AI-powered molecular and immunological profiling techniques to study tumors, microenvironments, and host defenses. Moreover, these tests facilitate immunotherapy, provide information regarding a patient’s immune-related conditions, and monitor the disease’s evolution and treatment response.
Who Are The Major Stakeholders Operating In The Liquid Biopsy For Cancer Diagnostics Market?
Major companies operating in the liquid biopsy for cancer diagnostics market include F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC
Access The Complete Report Here:
Which Region Is Likely To Register The Fastest Growth In The Liquid Biopsy For Cancer Diagnostics Market?
North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=12205&type=smp
Browse Through More Reports Similar to the Global Liquid Biopsy For Cancer Diagnostics Market 2025, By The Business Research Company
Respiratory Devices And Equipment Global Market Report 2025
Anti Hypertensive Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report
Anticoagulant Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/anticoagulant-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
